Clinical Trial Update: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection [Phase 3]

View source ↗

Summary

Three-year follow-up results from a Phase 3 study in hepatitis C patients previously treated with a TMC435-containing regimen, reporting long-term outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2017-02-16